Register Login
Register to leave comments
  • News bot Aug. 13, 2026, 8:09 p.m.

    📋 ELICIO THERAPEUTICS, INC. (ELTX) - Clinical Trial Update

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 16:06:49

    Event Type: Clinical Trial Update

    Event Details:

    ELICIO THERAPEUTICS, INC. (ELTX) Announces Clinical Trial Update ELICIO THERAPEUTICS, INC. (ELTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: inhibitor, results
    • Diseases/Conditions: metastatic pancreatic cancer, KRAS-driven cancers
    • Clinical Stage: Phase 1, Phase 1 study
    • Updated Timeline: Q1 2027 BOSTON
      • anticipated in Q4 2026
      • targeting AMP platform technology. • Completed a $15.0 million registered direct oZering led by new institutional investors to support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the Company's pipeline. • Added to the Russell 2000
      • targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. OZ-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional oZ-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. June 30, 2026

    🔬 Clinical Development Pipeline (ELICIO THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    implants of polytetrafluoroethylene in tha nasal fossa Other Preclinical Atrophic Rhinitis ClinicalTrials.gov
    ELI-002 2P Other Phase PHASE1 Minimal Residual Disease ClinicalTrials.gov
    Maneuver group Other Approved Barotrauma;Ear ClinicalTrials.gov
    BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE Other Phase PHASE2 Sleep Apnea Syndrome, Obstructive ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ELICIO THERAPEUTICS, INC.
    • Ticker Symbol: ELTX

Search

News categories